Global RNA Targeting Small Molecule Drug Discovery Market

Comprehensive Analysis On Size, Share, And Drivers Of The RNA Targeting Small Molecule Drug Discovery Market

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

Introduction: A Flourishing Market

  • RNA-targeting small molecule drug discovery market size skyrockets from $1.45 billion in 2023 to $1.78 billion in 2024.
  • Compound annual growth rate (CAGR) of 22.3% showcases exponential expansion.
  • Factors driving growth: Increased disease understanding, genomic breakthroughs, investment surge in biotech and pharma, rise of RNA therapeutics.

Prognosis: A Promising Future

  • Projected growth to $3.97 billion by 2028 at a CAGR of 22.2%.
  • Expansion drivers include RNA epigenetics research, AI integration, patient-centric approaches.
  • Key trends: RNA editing, CRISPR advancements, technological innovations.

Rising Disease Burden Is A Catalyst For Growth

  • Cancer, Genetic Disorders, and Viral Infections: Primary drivers of market growth.
  • RNA-targeted drug discovery crucial for treating these ailments.
  • Statistics on cancer prevalence and HIV underline the urgent need for innovative treatments.

Leading Players in the Arena

  • Industry Giants: F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, among others.
  • Diverse portfolio includes RNA targeting-based drug discovery.

View More On The RNA Targeting Small Molecule Drug Discovery Market Report 2024 –

Revolutionizing Small-Molecule Drug Discovery Through AI

  • AI Integration: Key trend shaping the industry.
  • Google Cloud’s initiatives expedite drug discovery.
  • AI predicts protein structure, expedites genetic data analysis.

Novo Nordisk’s Strategic Acquisition

  • Acquisition of DiceRNA Pharmaceuticals: Strengthens Novo Nordisk’s RNA-based drug discovery capabilities.
  • DiceRNA’s RNAi platform enriches Novo’s research arsenal.
  • Marks a significant milestone in the company’s growth trajectory.

Segmentation: Understanding the Market Dynamics

  1. By Target RNA Type: mRNA, ncRNA, miRNA, lncRNA.
  2. By Technology: CRISPR-Cas9, RNA Aptamers, siRNA, Ribozymes.
  3. By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders.
  4. By Delivery Method: IV, Oral, Topical.
  5. By Application: Research Use, Therapeutic Use, Diagnostic Use.

Regional Dominance: North America Leads

  • North America emerges as the largest region in 2023.
  • High concentration of key players and robust research infrastructure.

Conclusion: Pioneering Progress

  • The RNA-targeting small molecule drug discovery market witnesses unprecedented growth.
  • AI integration, strategic acquisitions, and segmentation strategies drive innovation.
  • With rising disease burden, the quest for effective treatments intensifies.
  • The future promises groundbreaking advancements in RNA therapeutics, offering hope to millions worldwide.

Request A Sample Of The Global RNA Targeting Small Molecule Drug Discovery Market Report 2024: